International?: Faulty trials sullied gefitinib that was approved. Survival in nsclc appeared better with erlotinib, but population differences were different, likely accounting for the effect rather than the drugs. Fda & pharma caution you not to look abroad. Caveat emptor. Canada?
Answered 7/29/2012
5.7k views
A doctor has provided 1 answer
8 doctors weighed in across 2 answers
4 doctors weighed in across 3 answers
6 doctors weighed in across 2 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question